SCHEMBL6281076

SCHEMBL6281076

CC(NC(=S)Nc1nccs1)c1cccs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
ALDH1A1 P00352 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
GAA P10253 2/20 0.52
NFKB1 P19838 2/20 0.52
HTT P42858 2/20 0.52
LMNA P02545 2/20 0.52
MEN1 O00255 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
CYP2C19 P33261 1/20 0.52
THPO P40225 1/20 0.52
MTOR P42345 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284560 0.81 NPC1 (0.56) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL10144116 0.77 ALDH1A1 (0.60) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL8197608 0.74 RAB9A (0.56) NPC1RAB9AALDH1A1SMN1; SMN2NFKB1
SCHEMBL6281340 0.74 NPC1 (0.57) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL6284442 0.74 NPC1 (0.57) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL6959411 0.74 ALDH1A1 (0.52) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL6963854 0.72 RAB9A (0.48) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL6965126 0.72 RAB9A (0.48) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL6287452 0.72 ALDH1A1 (0.42) NPC1RAB9AALDH1A1SMN1; SMN2GAA
SCHEMBL6959508 0.71 HPGD (0.49) NPC1RAB9AALDH1A1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960606-B2 Adamantyl Thiazole Thioureas PARKER HUGHES INSTITUTE (US) 2005-11-01 US disclosed
US-20030207921-A1 Aromatic and heterocyclic thiazolyl thiourea compounds and use PARKER HUGHES INSTITUTE (US) 2003-11-06 US disclosed
EP-1326852-A1 AROMATIC AND HETEROCYCLIC THIAZOLYL THIOUREA COMPOUNDS AND USE Parker Hughes Institute (US) 2003-07-16 EP disclosed
EP-1194427-B1 THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV PARKER HUGHES INST (US) 2003-03-05 EP disclosed
WO-2002032889-A1 AROMATIC AND HETEROCYCLIC THIAZOLYL THIOUREA COMPOUNDS AND USE PARKER HUGHES INSTITUTE (US) 2002-04-25 WO disclosed
EP-1194427-A1 THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV Parker Hughes Institute (US) 2002-04-10 EP disclosed
WO-2000078755-A1 THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV PARKER HUGHES INSTITUTE (US) 2000-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207921-A1 Aromatic and heterocyclic thiazolyl thiourea compounds and use TYMP, PNP, TPMT NPC1 985/4885RAB9A 2750/4885ALDH1A1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.